RankingsPricing
  1. US-listed companies
  2. AGIOS PHARMACEUTICALS, INC.
  3. Financials
  4. Stock-based compensation

AGIOS PHARMACEUTICALS, INC.AGIO

Market cap
$1.5B
P/E ratio
SummaryFinancials
Period EndStock-based compensation (Million USD)YoY (%)
Dec 31, 202443-4.29%
Dec 31, 202345-9.19%
Dec 31, 202249-7.87%
Dec 31, 202154-28.77%
Dec 31, 202075+3.80%
Dec 31, 201972-1.34%
Dec 31, 201873+53.44%
Dec 31, 201748+13.60%
Dec 31, 201642+31.67%
Dec 31, 201532+177.79%
Dec 31, 201412+279.74%
Dec 31, 20133

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)